Home » Stocks » SRNE

Sorrento Therapeutics, Inc. (SRNE)

Stock Price: $7.77 USD -0.22 (-2.75%)
Updated December 2, 4:00 PM EST - Market closed
Pre-market: $7.82 +0.05 (0.64%) Dec 3, 8:07 AM

Stock Price Chart

Key Info

Market Cap 2.04B
Revenue (ttm) 41.52M
Net Income (ttm) -289.78M
Shares Out 251.21M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE 2.36
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $7.77
Previous Close $7.99
Change ($) -0.22
Change (%) -2.75%
Day's Open 7.80
Day's Range 7.53 - 7.93
Day's Volume 8,573,540
52-Week Range 1.57 - 18.82

More Stats

Market Cap 2.04B
Enterprise Value 2.15B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 251.21M
Float n/a
EPS (basic) -1.42
EPS (diluted) -1.50
FCF / Share -0.64
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 75.39M
Short Ratio 4.90
Short % of Float n/a
Beta 2.87
PE Ratio n/a
Forward PE 2.36
P/FCF Ratio n/a
PS Ratio 49.21
PB Ratio 10.43
Revenue 41.52M
Operating Income -206.57M
Net Income -289.78M
Free Cash Flow -160.39M
Net Cash -102.74M
Net Cash / Share -0.39
Gross Margin -211.21%
Operating Margin -497.59%
Profit Margin -698.00%
FCF Margin -386.34%
ROA -19.12%
ROE -408.95%
ROIC -51.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.00*
Low
21.0
Current: $7.77
High
21.0
Target: 21.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue31.4321.191528.154.593.830.460.580.530.68
Revenue Growth48.31%-86.04%1762.81%77.6%20%731.52%-21.23%10.36%-22.47%-
Gross Profit19.2014.131487.342.641.780.460.580.530.68
Operating Income-259-15025.34-96.78-74.01-34.74-21.67-4.85-3.24-1.81
Net Income-292-2049.13-60.92-45.81-34.66-21.91-4.85-3.24-1.81
Shares Outstanding13310669.7450.3636.9126.6815.0511.419.928.83
Earnings Per Share-2.35-1.920.13-1.21-1.24-1.30-1.46-0.42-0.25-0.25
Operating Cash Flow-173-112-99.18-70.93-42.07-28.76-16.49-3.80-2.74-1.55
Capital Expenditures-11.44-11.20-10.97-6.86-3.71-0.59-0.42-0.55-1.05-0.05
Free Cash Flow-184-123-110-77.79-45.78-29.36-16.91-4.35-3.80-1.59
Cash & Equivalents80.7721320.8783.5013671.9031.675.093.475.28
Total Debt2912335.2147.329.2312.154.81---
Net Cash / Debt-210-19.9615.6636.1912759.7626.865.093.475.28
Assets55862443240234414292.586.784.575.69
Liabilities52541722531520332.8325.770.580.360.60
Book Value78.5920920080.0414510966.816.204.215.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sorrento Therapeutics, Inc.
Country United States
Employees 310
CEO Henry Ji

Stock Information

Ticker Symbol SRNE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SRNE

Description

Sorrento Therapeutics, a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.